Who makes KeraStat® Gel with Morphine application?

KeraStat® Gel with Morphine application is developed by The Metis Foundation.

What development phase is KeraStat® Gel with Morphine application in?

KeraStat® Gel with Morphine application is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

KeraStat® Gel with Morphine application

The Metis Foundation · FDA-approved active Small molecule Quality 0/100

KeraStat® Gel with Morphine application, marketed by The Metis Foundation, holds a niche position in the pain management segment. The drug's key strength lies in its unique mechanism of action, which differentiates it from other pain relief options. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	KeraStat® Gel with Morphine application
Sponsor	The Metis Foundation
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pilot Study: KeraStat® Gel for Topical Delivery of Morphine for Management of Non-Healing, Painful Open Wounds and Ulcers (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KeraStat® Gel with Morphine application CI brief — competitive landscape report
KeraStat® Gel with Morphine application updates RSS · CI watch RSS
The Metis Foundation portfolio CI